Individuals carrying specific genotypes of APOE (e2e3) were more prone to develop vancomycin-induced acute kidney injury (AKI), per se.

This could apply to other nephrotoxic agents as well.

We also observed a significant correlation between pharmacokinetic parameters and vancomycin-induced AKI.

Genotyping patients for specific polymorphisms before initiating pharmacotherapy would be used for risk stratification and dose adjustment for those genetically more prone to developing serious side effects such as AKI.

Among the screened patients, a total of 87 cases with 87 blood samples (trough level) were included in this study.

Read More